NextCure (NASDAQ:NXTC) Stock Rating Lowered by Zacks Investment Research

NextCure (NASDAQ:NXTC) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Tuesday, Zacks.com reports.

According to Zacks, “NextCure Inc. is a clinical-stage biopharmaceutical company. It is engaged in discovering and developing immunomedicines to treat cancer and other immune-related diseases. The company’s product candidate consists of NC318 and NC410 which are in clinical stage. NextCure Inc. is based in Beltsville, Maryland. “

A number of other analysts have also recently commented on the company. Morgan Stanley upped their price objective on NextCure from $25.00 to $33.00 and gave the company an “overweight” rating in a research report on Tuesday, August 13th. Bank of America boosted their price target on NextCure from $27.00 to $44.00 and gave the company a “buy” rating in a report on Monday, September 9th. Finally, Piper Jaffray Companies reissued a “positive” rating and set a $95.00 price target (up previously from $54.00) on shares of NextCure in a report on Monday, November 11th.

Shares of NXTC stock traded down $2.50 during trading hours on Tuesday, reaching $36.05. The company’s stock had a trading volume of 2,106,300 shares, compared to its average volume of 878,114. The company has a debt-to-equity ratio of 0.02, a quick ratio of 17.05 and a current ratio of 17.05. NextCure has a one year low of $13.86 and a one year high of $109.00. The business’s fifty day moving average is $34.99.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

NextCure (NASDAQ:NXTC) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02). The company had revenue of $1.58 million during the quarter, compared to the consensus estimate of $1.50 million. As a group, equities analysts predict that NextCure will post -2.23 EPS for the current year.

Large investors have recently added to or reduced their stakes in the business. Indus Capital Partners LLC bought a new stake in NextCure during the second quarter valued at about $1,407,000. BlackRock Inc. bought a new stake in NextCure during the second quarter valued at about $2,032,000. Fosun International Ltd bought a new stake in NextCure during the second quarter valued at about $2,247,000. Yale University bought a new stake in NextCure during the second quarter valued at about $1,865,000. Finally, Cormorant Asset Management LP bought a new stake in NextCure during the second quarter valued at about $14,980,000. 47.19% of the stock is owned by institutional investors and hedge funds.

About NextCure

There is no company description available for NextCure Inc

Read More: Why is total return important?

Get a free copy of the Zacks research report on NextCure (NXTC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Leave a Reply

Your email address will not be published. Required fields are marked *

*